131 related articles for article (PubMed ID: 3034033)
1. Baroreflex setting and sensitivity in normal subjects: effects of pharmacologic inhibition of the angiotensin I converting enzyme.
Düsing R; Kayser G; Wagner S; Scherf H; Glänzer K; Predel HG; Kramer HJ
Am J Cardiol; 1987 Apr; 59(10):50D-54D. PubMed ID: 3034033
[TBL] [Abstract][Full Text] [Related]
2. Acute effects of the new angiotensin converting enzyme inhibitor ramipril on hemodynamics and carotid sinus baroreflex activity in congestive heart failure.
Vogt A; Unterberg C; Kreuzer H
Am J Cardiol; 1987 Apr; 59(10):149D-154D. PubMed ID: 3034024
[TBL] [Abstract][Full Text] [Related]
3. Unchanged pressor effect of norepinephrine in normal man following the oral administration of two angiotensin converting enzyme inhibitors, captopril and HOE 498.
Vierhapper H; Witte PU; Waldhäusl W
J Hypertens; 1986 Feb; 4(1):9-11. PubMed ID: 3007605
[TBL] [Abstract][Full Text] [Related]
4. Sympathetic nervous activity and noradrenaline reactivity during angiotensin converting enzyme inhibition.
Philipp T; Sharma AM; Thiede HM; Kribben A
Am J Cardiol; 1987 Apr; 59(10):55D-59D. PubMed ID: 3034034
[TBL] [Abstract][Full Text] [Related]
5. The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers.
Bussien JP; Nussberger J; Porchet M; Waeber B; Brunner HR; Perisic M; Tansey MJ; Bomm M; Hajdu P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Mar; 329(1):63-9. PubMed ID: 2987705
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic effects of a single 10-mg dose of the angiotensin converting enzyme inhibitor ramipril in patients with impaired renal function.
Ocón-Pujadas J; Debusmann ER; Jane F; Lahn W; Irmisch R; Mora J; Grötsch H
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S45-8. PubMed ID: 2474101
[TBL] [Abstract][Full Text] [Related]
7. Effects on autonomic function of a new angiotensin converting enzyme inhibitor, ramipril.
Sugimoto K; Kumagai Y; Tateishi T; Seguchi H; Ebihara A
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S40-4. PubMed ID: 2474100
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, converting enzyme inhibition and peripheral arterial hemodynamics of ramipril in healthy volunteers.
Thuillez C; Richer C; Giudicelli JF
Am J Cardiol; 1987 Apr; 59(10):38D-44D. PubMed ID: 3034032
[TBL] [Abstract][Full Text] [Related]
9. Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.
Böhm RO; van Baak MA; Rahn KH
Eur J Clin Pharmacol; 1986; 30(5):541-7. PubMed ID: 3019702
[TBL] [Abstract][Full Text] [Related]
10. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important.
Wenting GJ; Blankestijn PJ; Poldermans D; van Geelen J; Derkx FH; Man in't Veld AJ; Schalekamp MA
Am J Cardiol; 1987 Apr; 59(10):92D-97D. PubMed ID: 3034041
[TBL] [Abstract][Full Text] [Related]
11. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers.
Witte PU; Metzger H; Eckert HG; Irmisch R
Arzneimittelforschung; 1984; 34(10B):1448-51. PubMed ID: 6097272
[TBL] [Abstract][Full Text] [Related]
12. Acute hemodynamic and hormonal effects of ramipril in chronic congestive heart failure and comparison with captopril.
de Graeff PA; Kingma JH; Dunselman PH; Wesseling H; Lie KI
Am J Cardiol; 1987 Apr; 59(10):164D-170D. PubMed ID: 3034026
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril.
Predel HG; Düsing R; Bäcker A; Kipnowski J; Kramer HJ
Am J Cardiol; 1987 Apr; 59(10):143D-148D. PubMed ID: 3034023
[TBL] [Abstract][Full Text] [Related]
14. Synergism of CE-inhibition and diuresis. A study with ramipril, piretanide and HCT in SHR.
Becker RH; Baldes L; Treudler M
Clin Exp Hypertens A; 1987; 9(2-3):357-60. PubMed ID: 3038394
[No Abstract] [Full Text] [Related]
15. Cardiovascular effects of the converting enzyme inhibitor ramipril (HOE 498) in anesthetized dogs with acute ischemic left ventricular failure.
Schölkens BA; Martorana PA; Göbel H; Gehring D
Clin Exp Hypertens A; 1986; 8(6):1033-48. PubMed ID: 3019594
[TBL] [Abstract][Full Text] [Related]
16. Effect of angiotensin-converting enzyme inhibitor Hoe-498 on noradrenaline-induced vasoconstriction in isolated perfused mesentery of rats.
Xiang JZ; Schölkens BA
Zhongguo Yao Li Xue Bao; 1984 Jun; 5(2):104-5. PubMed ID: 6087609
[No Abstract] [Full Text] [Related]
17. Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers.
Doering W; Maass L; Irmisch R; König E
Am J Cardiol; 1987 Apr; 59(10):60D-64D. PubMed ID: 3034035
[TBL] [Abstract][Full Text] [Related]
18. Twenty-four hour changes in active and inactive renin after various oral doses of the converting enzyme inhibitor ramipril (HOE498) in normal man.
Malatino LS; Manhem P; Ball SG; Leckie BJ; Morton JJ; Murray GD; Robertson JI
J Clin Hypertens; 1986 Sep; 2(3):231-7. PubMed ID: 3023553
[TBL] [Abstract][Full Text] [Related]
19. A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man.
Manhem PJ; Ball SG; Morton JJ; Murray GD; Leckie BJ; Fraser R; Robertson JI
Br J Clin Pharmacol; 1985 Jul; 20(1):27-35. PubMed ID: 2992562
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Schölkens BA; Becker RH; Kaiser J
Arzneimittelforschung; 1984; 34(10B):1417-25. PubMed ID: 6097268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
